{"entity":{"id":"nct06598527","kind":"trial","name":"Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant The","aka":["SACTION2401"],"tldr":"A phase 3 trial of tislelizumab in lung cancer, run by Yang Hong, now recruiting.","summary":"Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage II-III Non-small Cell Lung Cancer: A Phase III, Randomized, Multicenter, Prospective Study is a phase 3, randomised interventional study registered as NCT06598527 by Yang Hong, with a registry enrolment figure of 360 participants, started 2024-10-15 and due to reach its primary completion in 2027-01-30. Interventions recorded: Stereotactic body radiotherapy (SBRT); Tislelizumab; Chemotherapy. Conditions listed: Lung Cancer (NSCLC). Primary outcome: event-free survival. Lung eligibility wording from the registry: \"Patients with cytologically/histologically diagnosed (by means of percutaneous lung aspiration biopsy, bronchoscopy, mediastinoscopy, etc\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06598527","url":"https://clinicaltrials.gov/study/NCT06598527"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["resectable-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","sbrt"],"targets":[],"drugs":["tislelizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06598527","phase":"3","setting":"Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage II-III Non-small Cell Lung Cancer: A Phase III, Randomized, Multicenter, Prospective Study","sponsor":"Yang Hong","enrolled":360,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06598527/","neighbours":{"cancer":[{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"}],"drug":[{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}